Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New imaging method could improve pelvic pain treatment

NCT ID NCT07605598

Knowledge-focused Sponsor: University of California, Los Angeles Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aims to better understand and treat myofascial pelvic pain, a common cause of long-term pelvic pain in women. Researchers will use a noninvasive imaging technique to measure pelvic floor muscle function before and after three different treatments: education with relaxation exercises, physical therapy, or vaginal medication. The study will enroll 120 adult women with pelvic pain for at least three months and follow them over six months to see which treatment works best.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Jul 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Women over 18 years of age Pelvic Pain for more than 3 months Report an average daily pain intensity score of at least 4 on a 0 to 10 scale Palpable trigger/tender points in internal pelvic floor muscles on standardized myofascial pelvic floor exam Willing to refrain from new clinical treatment that may affect pain during the study period Exclusion Criteria Inability to participate in clinic visits Prior invasive pelvic procedures for pain (e.g., prior pelvic surgery, sacral neuromodulation, intradetrusor Botox®) in the past 6 months Active UTI or vaginal infection Pregnancy or childbirth in the past 12 months, currently planning a pregnancy Illicit Drug addiction/regular use of controlled substances (including marijuana use in the past 2 weeks or during the study period) Pelvic floor physical therapy in the past 3 months Malignancy or other serious medical condition (e.g., poorly controlled diabetes \[HgA1c \> 8\], chronic renal disease \[GFR \<30\], neurologic or rheumatic disease) Diagnosed with an alternate cause of pelvic pain (e.g., ulcerative interstitial cystitis, vestibulodynia, vulvar dermatoses, dysmenorrhea) Urinary retention with a PVR \>150 mL Greater than stage 3 pelvic organ prolapse Indwelling vaginal devices (e.g., pessary, contraceptive ring. Not including Mirena IUD) that cannot be removed for the study Inability to sign an informed consent, fill out questionnaires, or complete study interviews

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic pelvic pain are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Facial Pain myofascial pain syndrome Pelvic Pain vaginismus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic pelvic pain Myofacial pain Myofascial pelvic pain Pelvic pain

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • UCLA

    Los Angeles, California, 90095, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.